MedTrace Logo

Appropriate Dosing to Optimise Personalised Cancer Treatments

NCT04154163 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2022-02-28

No results posted yet for this study

Summary

This is a pilot study to assess feasibility of dried blood spot (DBS) samples for pharmacokinetic measurements of targeted anti-cancer drugs in oncology patients such as patients with BRAF-mutant melanoma receiving targeted treatment with BRAF and MEK inhibitors.

Conditions

  • Melanoma Stage III
  • Melanoma Stage IV
  • Ovarian Cancer
  • Renal Cancer Stage III
  • Renal Cancer Stage IV
  • Lung Cancer, Non-small Cell

Interventions

DIAGNOSTIC_TEST

Dried blood Spot (DBS)

Dried Blood Spot filter paper and sponges

DIAGNOSTIC_TEST

Venous blood sampling

Venous blood

Sponsors & Collaborators

  • University of Dundee

    lead OTHER

Principal Investigators

  • Charlotte Proby, MBBS,FRCP · Chief Investigator

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-10
Primary Completion
2021-03-05
Completion
2021-03-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04154163 on ClinicalTrials.gov